Jefferies Financial Group Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK)

Equities research analysts at Jefferies Financial Group began coverage on shares of Stoke Therapeutics (NASDAQ:STOK - Get Free Report) in a research report issued to clients and investors on Friday, MarketBeat reports. The brokerage set a "buy" rating and a $30.00 price target on the stock. Jefferies Financial Group's target price indicates a potential upside of 143.70% from the stock's previous close.

A number of other analysts also recently issued reports on STOK. HC Wainwright dropped their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $25.80.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.91 during trading on Friday, hitting $12.31. The stock had a trading volume of 617,038 shares, compared to its average volume of 680,001. The company's 50 day moving average price is $10.97 and its two-hundred day moving average price is $9.61. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $16.15. The stock has a market cap of $672.13 million, a price-to-earnings ratio of 15.58 and a beta of 1.14.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider owned 25,782 shares of the company's stock, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in Stoke Therapeutics by 29.2% during the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after buying an additional 4,512 shares during the period. GAMMA Investing LLC raised its holdings in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Stoke Therapeutics by 123.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock valued at $1,053,000 after acquiring an additional 52,813 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Stoke Therapeutics during the 4th quarter valued at about $1,423,000. Finally, Bank of New York Mellon Corp grew its stake in Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after acquiring an additional 1,330 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.